



Postponement of the publication of the 2026 half-year results and the half-yearly financial report as at 28 September

Montpellier, France, July 24th, 2026, 05:45 PM. **Intrasense (FR0011179886 – ALINS)**, a French expert in AI-enhanced medical imaging solutions facilitating diagnosis, decision-making and therapeutic follow-up, announces the postponement of the publication of its 2026 half-year results and half-year financial report, originally scheduled for 15 September 2026. This postponement follows a change in the schedule of the Guerbet Group.

Next financial announcement:

2026 Half-Year Results: September 28 (after market close)

About Intrasense

A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group since 2023, Intrasense develops medical imaging software solutions that are now firmly focused on artificial intelligence.

Intrasense's product portfolio includes:

- Myrian® (currently being divested), an advanced visualization platform equipped with state-of-the-art clinical tools that simplifies the interpretation of all types of images.
- DUOnco™: a suite of AI algorithms specialized in oncology, including those for the detection of pancreatic lesions and focal liver lesions, as well as the world's first CE-certified AI dedicated to bone lesions.
- Liflow® (still in the controlled-release phase), a solution designed for the longitudinal monitoring of oncology patients.

By combining clinical expertise and operational excellence, Intrasense provides healthcare professionals with tools of high medical value that facilitate the analysis, diagnosis, and care of patients.

For more information, visit: www.intrasense.fr

Contacts

INTRASENSE

Communication officer

Mathilda Vigne-Salade
Phone: +334 67 13 01 30
investisseurs@intrasense.fr

SEITOSEI.ACTIFIN

Analyst & Investor Relations

Foucauld Charavay
Phone: +336 37 83 33 19
intrasense@seitosei-actifin.com

Press Relations

Isabelle Dray
Phone: +33 6 85 36 85 11
isabelle.dray@seitosei-actifin.com